Molecular landscape in adult acute myeloid leukemia: where we are where we going?
Review Article

Molecular landscape in adult acute myeloid leukemia: where we are where we going?

Daniela Damiani, Mario Tiribelli

Division of Hematology and SCT, Department of Medical Area, University of Udine, Udine, Italy

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Daniela Damiani, MD. Division of Hematology and Stem Cell Transplantation, Department of Medical Area, University of Udine, 33100 Udine, Italy. Email: daniela.damiani@uniud.it.

Abstract: The last years has further unraveled the genetic complexity of acute myeloid leukemia (AML). Traditionally, AML risk stratification has relied on cytogenetic markers, defining three categories (favorable, intermediate and unfavorable); however, chromosomal abnormalities are present only in about 50% of AML cases. The identification of mutation in FLT3, NPM1 and CEPBA genes permitted to better define prognosis in patients with cytogenetically normal AML and are presently included in the classification of AML. Subsequently, recognition of many different gene mutations and epigenetic variance, such as RAS, DNMT3A, IDH1 and IDH2, ASXL1, TET2 and others, have been used in diagnosis and prognostication AML. Unfortunately, this numerous biological evidence has not yet translated in a significance advance in therapeutic strategies, that is largely based on the traditional approach used over the past four decades. In this review we aim to summarize the most recent advances in molecular markers of AML, with especial focus on targetable mutations that may route the development of novel therapies for this dreadful disease.

Keywords: Acute myeloid leukemia (AML); prognosis; molecular genetics; epigenetics; whole genome sequencing; target therapies


Received: 03 July 2018; Accepted: 19 September 2018; Published: 23 April 2019.

doi: 10.21037/jlpm.2018.09.08


Introduction

Acute myeloid leukemia (AML) is a neoplastic disease of the hematopoietic stem cell defined by impaired differentiation capacity, clonal expansion and accumulation of immature cells with suppression of polyclonal residual hematopoiesis. The resulting peripheral cytopenias accounts for the most frequent clinical symptoms at diagnosis (fatigue, dyspnea, fever and infections, hemorrhage) and the leukemic cells “tropism” for tissues outside blood and bone marrow justifies the other symptoms characterizing AML clinical course. Since the first attempt of classification, proposed in 1976 by the French-American-British (FAB) Group, the diagnosis is based on the morphological identification and quantification of “blast cells” in bone marrow smears. However, over the past 40 years, it has become evident that the initial FAB criteria and their subsequent modifications are far to capture the real clinical and biological variability of the disease and, even less, to predict prognosis. The identification of recurrent cytogenetic abnormalities not only provided the first hint in understanding leukemia biology but soon became one of the most powerful tool to define AML risk, driving clinician decision-making (1-6). Unfortunately, despite the improvement of cytogenetic techniques, the conventional G-banding karyotyping fails to identify structural and/or numerical chromosomal alterations in about 45% of patients at diagnosis. These patients are arbitrarily included in the intermediate risk group, even if outcomes are largely heterogeneous and the optimal therapeutic approach is not clear. Advances in molecular genetics, initially focused on explaining the clinical heterogeneity of patients with cytogenetically normal (CN) AML, led to the identification of various somatic mutations, often with prognostic impact, that have eventually been included in the recently revised WHO and European LeukemiaNet (ELN) classification of myeloid neoplasms (4,7). Moreover, the diffusion of the parallel sequencing diagnostic platforms, permitted the evaluation of mutational profiling in the whole-exome or in the whole-genome, identifying driving and co-occurring mutations in more than 95% of patients, thus paving the way to a genome-based AML grouping, each with distinct clinical phenotype and outcome (8,9).

Herein we aimed to overview the most relevant molecular markers in AML with a focus on their prognostic significance and on their potential use to develop new therapies with molecular targets.


Molecular mutations resulting in chromosomal rearrangements

PML-RARA

The fusion protein PML-RARA results from the balanced chromosomal translocation t(15;17)(q24;q21) and is the hallmark of acute promyelocytic leukemia (APL). The PML-RARA rearrangement is present in >98% of APL cases and defines a diagnosis of APL regardless of blast percentage (De Braekeleer et al., Exp Rev Hematol 2014). The fusion protein releases the cell from the transcriptional control of retinoic acid (RA), thus repressing the transcription of genes involved in physiological myeloid differentiation. This pathological block can be overcome by greatly increasing the level of RA; so, the addition of all-trans retinoic acid (ATRA) to conventional chemotherapy or, more recently, arsenic trioxide has transformed APL from one of the most heinous to the most curable acute leukemia (Kayser et al., Leukemia 2018).

RUNX1-RUNX1T1 (formerly AML1-ETO) and CBFB-MYH11

AML carrying one of the two reciprocal chromosomal translocations t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22), resulting in the gene rearrangements RUNX1-RUNX1T1 (previously known as AML1-ETO) and CBFB-MYH11 respectively, are collectively defined as core binding factor (CBF) leukemias (Sohl et al., Am J Hematol 2014). These abnormalities involve two distinct subunits of the CBF transcriptional protein, that is pivotal for normal hematopoiesis. RUNX1, formerly known as acute myeloid leukemia 1 (AML1), gene encodes for the CBFA2 subunit, that regulates DNA binding with CBFB. Both subunits are necessary for the correct functioning of the transcriptional complex, and translocations involving either of them result in a reduced transcription of different targets such as GM-CSF, MPO and IL3 and epigenetic silencing of others. Though the two CBF AML are generally considered together, there is a significant heterogeneity, mainly in the molecular signature, within this group of patients, resulting in different outcome (Sinha et al., Semin Hematol 2015).

Mixed lineage leukemia (MLL)

MLL gene, located on chromosome 11q23, is expressed in hematopoietic cells and encodes for a histone methyltransferase involved in epigenetic regulation of transcription (Muntean AG & Hess JL, Annu Rev Pathol 2012). MLL is involved in translocations with over a hundred partner genes, that has been described in adult and pediatric cases of AML, acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS) (Meyer C et al., Leukemia 2013); overall, an MLL translocation is found in about 10% of acute leukemias. The fusion with partner genes transforms MLL in a leukemogenic effector by deregulating transcriptional control. Despite the wide number of partner genes, MLL translocations are generally associated with adverse outcomes.


Somatic mutations in AML

Nucleophosmin (NPM1)

Nucleophosmin is a highly conserved, ubiquitous nucleolar phosphoprotein with a molecular weight of 37 kDa, coded by a gene containing 12 exons on chromosome 5q35. By continuously shuttling between cellular compartments, NPM1 act as a chaperon protein, involved in many processes critical for cellular homeostasis, such as ribosome biogenesis and transport, apoptotic response to stress stimuli, maintenance of genomic stability by control of cellular ploidy, DNA repair, chromatin condensation/decondensation (10). NPM1 knockout mice show abnormal organogenesis and lethal defects in primitive hematopoiesis. Heterozygous NPM1 knockout mice develop a myelodysplastic-like syndrome and have increased susceptibility of development of myeloid and lymphoid malignancies (11), supporting the hypothesis of a direct role of NPM1 in tumorigenesis which would act both as proto-oncogene and tumor suppressor gene (12). In solid tumors NPM1 function is increased through protein overexpression and its increase level has been associated with tumor stage or disease progression through increased Myc-dependent hyperproliferation (13-19). In hematologic disease NPM1 function is mostly perturbed by mutations in the C-terminal region. Haplo-insufficiency of the gene results in the reduction of the protein level in the nucleolus with a loss of function phenotype, and, through dimerization, in the cytoplasmic mis-localization of wild type and mutated protein. The cytoplasmic sequestration of the protein (c+NPM1), is associated with a gain of function phenotype due to its chaperone interaction with a number of tumor suppressor molecules, ultimately leading to the inhibition of p53 activity (20). NPM1 mutations are found in about 50–60% of cases with normal cytogenetics and in 30% of all cases, making them the most frequent genetic lesions in AML (21). Since the first description by Falini and colleagues in 2005 (22), the recognition of biological importance of NPM1 mutations as founder genetic lesions in leukemogenesis and the clinical impact of NPM1 mutations led to inclusion of NPM1 mutated AML as a distinct leukemic entity in the 2016 WHO classification. NPM1 mutations are usually restricted to exon 12 and are heterozygous with a retained wild type allele (23). To date, more than 50 molecular variants have been identified (24), named alphabetically from A to F in order to their discovery. The type A mutation, consisting of a “TCTG tetranucleotide tandem duplication” is the most common, accounting for 75-80% of cases. Mutations from B to D (15%) carry tetranucleotide insertions, the other rare mutations have variable size insertions. Despite their diversity, NPM1 gene variants product all the same biological effect, i.e., they alter the tryptophan residues crucial for nucleolar localization and create of a new nuclear export motif at the C-terminus with consequent cytoplasmic accumulation of the aberrant protein (25). NPM1 mutations are highly stable in disease history (26-28) and the very rare loss of NPM1 mutations seems to be associated with the acquisition of new cytogenetic abnormalities (29).

NPM1 mutations are more frequent in “de novo “leukemia and usually detectable in all leukemic cells. They precede associated mutations and are mutually exclusive with other recurrent genetic abnormalities. Moreover, leukemic cells have a distinct gene, microRNA and methylation expression signature (30-32). Disease onset is characterized by hypercellular bone marrow and multilineage involvement, high peripheral white blood cell/blast cell counts and high incidence of gingival and lymph node invasion. c+NPM1 blast cells did not have specific morphology, but cytotype is more often M4 or M5 and immunophenotype is mostly CD34 negative with strong CD33 expression (33-35). NPM1 mutations have been associated with good response to induction therapy (22) and, in CN-AML, NPM1 mutations seem to overcome the negative prognostic impact of multilineage dysplasia (36). In a meta-analysis of nine studies including 4,509 subjects, Liu and colleagues confirmed the favorable effect of NPM1 mutations on complete remission (CR) rates, disease free survival (DFS) and overall survival (OS) (37). However, many studies have demonstrated that positive prognostic impact of NPM1 mutations is largely dependent from the absence of concomitant Flt3-ITD mutation (35,38-40) or from Flt3-ITD with low allelic burden (41-43), so that this category has been added to favorable risk group in the ELN 2017 recommendations (4). Less defined is the prognostic role of the different mutation sub-groups. Koh and colleagues, in a small cohort of 18 patients observed a trend to better outcome in patients with group A mutations (44); Pastore and colleagues did not found prognostic differences among mutations subgroups (45). Alpermann and colleagues demonstrated a negative impact on event free survival (EFS) by type A mutations and found an additional negative effect in presence of concurrent mutations, such as Flt3-ITD and DNMT3a (46).

With this background, qualitative detection of different type NPM1 mutation is mandatory at AML diagnosis. Moreover, since the stability of mutations, peripheral blood quantitative PCR has been demonstrated a highly sensitive method for minimal residual disease (MRD) monitoring and personalized patient management (47,48).

The high frequency of NPM1 mutation and the better knowledge of wt- and c+NPM structure and functions have increased the efforts to identification NPM1 targeted drugs. Different target strategies are, at present, under investigation.

Interference with NPM1 oligomerization

NSC34884 is a small molecule inhibitor able to disrupt the hydrophobic region required for NPM1 oligomerization inducing the apoptosis of leukemic cells (49). At low doses NCS34884 seems to have higher sensitivity for haploinsufficient NPM1-mutated compared to NPM1-wt leukemic cells and ATRA and doxorubicin show a synergistic effect (50,51).

Targeting nucleolar assembly

CIGB-300 is a synthetic peptide able to bind NPM1 preventing its phosphorylation by casein kinase-2. Inhibition of CK-2 mediated NPM1 activation results in damage to the nucleolar architecture and to apoptosis induction (52).

Selective inhibition of nuclear export

Selinexor (KPT 330) is an oral selective inhibitor of exportin 1 (XPO1), protein involved in cytoplasmic NPM1-mutated mis-localization. Exportin 1 inhibition by selinexor increases apoptosis and induces myeloid differentiation through p53 and CEPBA upregulation (53,54). The major limitation of selinexor is its lack of specificity for leukemic cells and its side effects. A second generation of XPO1 inhibitor, KPT-8602 has been recently demonstrated higher activity and reduced toxicity in preclinical models (55) and is under investigation in a phase 1/2 trial (NCT02649790).

Nucleus translocation of c+NPM1

Oridonin is a natural product isolated from Rabdosia rubescens commonly used in a Chinese traditional medicine for its anti-carcinogenesis and anti-inflammatory properties. In vitro leukemia models have demonstrated its ability to revert the cytoplasmic mis-localization of mutated and wt NPM1. As a consequence, the stabilization of p14arf and p53 increases apoptosis (56). Avrainvillamide is a small molecule inhibitor isolated from a marine fungal strain of Aspergillus sp. able to bind the C-terminal DNA binding domain of c+NPM1, and to re-localize the mutated protein in the nucleoli, with a mechanism currently unknown (57).

Selective C+NPM1 destruction

All-trans retinoic acid (ATRA) and arsenic trioxide (ATO), currently used for the treatment of acute promyelocytic leukemia, have been recently demonstrated high activity also in NPM1 mutated acute leukemia. In cell lines, ATO seem induce apoptosis especially in those carrying type A mutation and ATRA have a synergistic effect. They selectively trigger c+NPM1 degradation, probably for its lower resistance to oxidative stress induced by ATO, while the levels of NPM1-wt remain unchanged (58).

Proteasomal c+NPM1 degradation

EAPB0503 is an analog of imiquimod, known to have very high activity on melanoma cells. It has recently proposed as target drug in NPM1 mutated acute leukemia for its ability to promote c+NPM1 degradation and to correct the wtNPM1 mis-localization, stabilizing p53 and inhibiting leukemia cell growth (59).

FLT3

FLT3 is a membrane-bound receptor with tyrosine kinase activity, involved in regulation of proliferation and differentiation of early hematopoietic progenitors. It belongs to the class III tyrosine kinase (TK) group and shows a high sequence and structural homology with platelet-derived growth factor receptor, c-kit and c-fms. The molecule contains an extra cellular immunoglobulin-like domain binding the cytokine Fms-like TK 3 ligand (FL), a transmembrane domain, and an intracellular domain that consist of a juxtamembrane dimerization segment, a TK domain interrupted by a short kinase insert and a C-terminal tail. Upon interaction with its ligand, the unphosphorylated monomeric receptor undergoes dimerization and the activation of various downstream effectors ultimately regulates the hematopoietic homeostasis. In hematopoietic malignancies overexpression of wild type protein was commonly found and it was hypothesized that very high level of FLT3-wt may promote constitutive activation of the receptor in malignant cells and may negatively affect prognosis (60,61). However, mutations of FLT3 are among the most common genetic abnormalities observed in AML, affecting either the juxtamembrane or the TK domain of the receptor.

FLT3-internal tandem duplication (FLT3-ITD)

Mutations in the juxtamembrane region consist of the “head to tail” duplication of small sequences, variable from 3 to more than 400 base pairs, resulting in the transcription and translation of a receptor with an elongated juxtamembrane domain. The consequence is the disruption of a regulatory segment preventing the adoption of active configuration in absence of ligand binding, leading to cytokine-independent phosphorylation, constitutive dimerization of the receptor and increased cellular proliferation (62-64). In addition to intracellular pathways activated by FLT3-wt, such as Ras/MEK/Erk and Akt/PI3K, the mutated receptor promotes STAT5 phosphorylation. So, different STAT5 target genes, not expressed upon physiological FL binding, are involved. They includes the activation of gene regulating cell-cycle, accounting for the proliferative advantage of FLT3-ITD mutated cells, but also the suppression of gene coding for myeloid differentiation transcription factors, such as PU.1 and CEBPα (65-67) and an increased production of reactive oxygen species and DNA breaks favoring genomic instability (68). Moreover, FLT3-ITD harboring cells acquire survival advantage through the suppression of the pro-apoptotic regulator transcription factor FOXO3a (69). Many studies in transgenic mouse models demonstrated that FLT3-ITD promotes the development of a myeloproliferative disease with splenomegaly, expansion of myeloid compartment, decrease of B cell compartment and exhaustion of HSC as a result of the their increased cell-cycle entry (70-73).

In adult AML, FLT3-ITD occurs in 15–20% of all patients and in 28–35% of those with normal cytogenetics (74) and is strongly associated with poor prognosis. Adult FLT3-ITD AML has lower CR rate, higher relapse risk and worse survival (43,75-80).

FLT3-ITD seems to affect outcome also after stem cell transplantation, a procedure that, due to the relevant relapse risk and dismal OS attained with standard chemotherapy, is generally recommended in FLT3-ITD positive patients in first CR (81).

In elderly patients the incidence and the prognostic role of FLT3-ITD is less defined. In a study of Southwest Oncology Group (SWOG) including 140 AML patients aged >55 years the incidence of FLT3-ITD was similar to that of younger patients, and was associated to disease resistance but did not impact on OS (82). Similar results were found by Daver and colleagues in 388 elderly patients, even if in this series FLT3-ITD was detected only in 12%. The authors explained the lack of prognostic power of FLT3-ITD with the presence, in these elderly patients, of many other negative prognostic factors that may overcome the power of FLT3 mutations (83). Conversely, subgroup analysis from other studies demonstrated an association between FLT3-ITD and poor prognosis in elderly AML (84,85).

There is increasing evidence that, besides the mere presence of ITD, outcome is influenced by FLT3-ITD allelic variation (i.e., mutant to wt allelic ratio) (75,77,86-88). Schlenk and colleagues reported that only patients with a high allelic ratio (≥0.51) took advantage from allogeneic stem cell transplantation (42). According with these observations, ELN 2017 recommendations have included FLT3-ITD with low allelic burden and concomitant NPM1 mutation in the favorable risk group (4). Variability of allelic ratio may be in part explained by loss of heterozygosity (LOH) of wild type allele, involving the entire 13q region telomeric to FLT3, in part by the co-existence in the same disease of leukemic sub-clones with different FLT3 mutation status (89).

Mutations in the TK domain (FLT3-TKD)

FLT3-TKD mutations are missense point mutations in exon 20 of TK domain, occurring in about 5–10% of AML patients; in contrast to age-dependent increase of FLT3-ITD, the prevalence of point mutations is stable through all ages. The most common is a nucleotide substitution at codon 835 causing the change of an aspartic acid to tyrosine (D835Y). However, other point mutations, deletions, and insertion within or in the surrounding codons have been reported (75,90,91). As a consequence, the TK domain remains in an “open conformation” permitting the binding of ATP, and the ligand independent receptor phosphorylation. Moreover, despite both FLT3-ITD and FLT3-TKD mutations promote constitutive activation of the receptor, they differ in downstream activation pathways and in induced genetic programs (92-94). TKD mutations do not activate STAT5, and this fact not only impacts the lineage phenotype of the disease, but in mouse model results in a less aggressive malignancy (95-98). However, the prognostic relevance of FLT3-TKD is still controversial (86,99-101) and, in the era of molecular therapies FLT3-TKD mutations may represent a potential target for specific direct inhibition.

Based on the exiting success of tyrosine kinase inhibitors in chronic myeloid leukemia, over the past 10 years, many small molecules targeting FLT3-TK by competing for the ATP binding site have been developed and entered clinical trials. As monotherapy, they only gave a transient clearance of peripheral blood and bone marrow leukemic cells. Moreover, their initial efficacy was often loss due to the emergence of secondary mutations or the activation of alternative intracellular activation pathways. The actual advantage in combination with chemotherapy is still under investigation and for an exhaustive review of the current ongoing clinical trials we refer to the manuscript by Assi and Ravandi (102).

FLT3 inhibitors are commonly classified by their potency and by the specificity of inhibition. The first generation of inhibitors includes non-selective molecules, such as sunitinib, sorafenib, lestaurtinib and midostaurin, able to affect many other intracellular pathways (such as PDGFR, VEGFR, Kit, JAK2). Among them, sunitinib, approved for the treatment of renal and hepatocellular carcinomas, and lestaurtinib have not been further investigated after early trials’ results because of significant toxicity and low efficacy in AML, both as single agent or in combination with chemotherapy (103-106). Sorafenib has been employed in many phase I/II trials, demonstrating acceptable toxicity and better efficacy, also in combination with chemotherapy or hypomethylating agents, and in elderly patients (107-111). Midostaurin is, to date, the only FLT3 inhibitor approved in the US and Europe for the treatment of adult, newly diagnosed, FLT3 mutated AMLs in combination with standard chemotherapy. In a population of patients aged less than 60 years, positive for an FLT3 mutation, the registration trial (Ratify, NCT00651261) clearly demonstrated that the addition of midostaurin significantly prolonged OS (74.7 vs. 25.6 months in patients receiving placebo; P=0.009). Moreover, midostaurin provided an increase in EFS (8.3 vs. 3.0 months, P=0.002) and its benefit was confirmed in all three FLT3 subgroup (FLT3-TKD, FLT3-ITD low and FLT3-high allelic ratio) (112). Many other trials aimed to test the activity of midostaurin in prevent relapse after standard chemotherapy or SCT, or in elderly patients in combination with hypomethylating agents are ongoing (102).

The second generation of FLT3 inhibitors includes molecules with high potency and specificity against FLT3. Quizartinib demonstrated, in vitro, a 10-fold lower activity on other receptor TKs and a very high potency against FLT3 and, in vivo, a good tolerability profile (113). A phase III randomized trial exploring the efficacy of standard chemotherapy plus quizartinib or placebo in untreated FLT3-ITD mutated patients is ongoing (Quantum-First, NCT02668653). Crenolanib shows activity not only against ITD but also TKD mutations. Various trials evaluating crenolanib activity in combination with conventional chemotherapy or hypomethylating agents or as maintenance therapy after SCT are currently active (102). As crenolanib, gilteritinib have high potency and selectivity against FLT3-ITD and TKD mutations. Moreover, for its activity against AXL kinase, it appears a molecule potentially able to escape resistance (114).

To counteract the rapid emergence of resistance remains the major challenge in the use of FLT3 inhibitors. Despite the low prognostic significance of TKD mutations at diagnosis, the acquisition of additional point mutation under inhibitor pressure can induce resistance to many compounds of the same class. However, it is becoming evident that a major role in resistance is played by the activation of alternative intracellular pathways, so new strategies preventing the development of resistance or sensitizing leukemic cells to inhibitors are needed.

CEPBA

CCAAT enhancer binding protein alpha is a transcription factor coded on an intronless gene on chromosome 9q13.1, involved in differentiation of many tissues (115) and, in hematopoietic system, in driving early myeloid precursors to granulocyte or monocyte maturation (116,117). Moreover, recent data demonstrated its role in proliferation control and self-renewal capacity of hematopoietic stem cells (116). In CEPBA deficient mice models, neutrophil maturation reaches only the myeloblast stage, resembling the clinical feature of leukemia patients. In AML, CEPBA mutations occur in 5–10% of “de novo” cases, with a higher incidence in CN-AML and in those with 9q deletion (21). Compared to other subtypes, CEPBA-mutated AML tends to have lower platelets counts, higher hemoglobin levels, higher peripheral blast percentages and rarer extra medullary involvement. Though lacking specific morphologic characteristics, CEPBA+ cases show frequent aberrant surface expression of CD7 (118). In acute leukemia two major CEPBA mutations have been described: at the N-terminal region, resulting in a nonfunctional truncated protein due to a premature termination of the synthesis, or at the C-terminal region, in which in-frame deletions or insertions impair its DNA binding and dimerization ability. About two-thirds of AML patients display two mutations (biallelic or double mutations), while the remaining third carry single allele mutation (119). Only biallelic mutation is associated with favorable prognosis, retained despite the presence of associated multilineage dysplasia (120-122). Patients with a single mutation show contradicting outcome (123). Furthermore, the positive effect of CEPBA double mutation on survival is confirmed also in patients who acquired mutation at relapse (124). Data emerging from gene expression profiling confirmed the distinct gene expression signature associated with biallelic CEPBA mutations, so this AML subgroup has been recognized as a distinct diagnostic entity by the 2016 WHO classification of myeloid neoplasms (7). In mouse models CEPBA-induced leukemogenesis demonstrated that N-terminal and C-terminal mutations have different impact on stem cell homeostasis. The maximum leukemogenic effect was obtained when a C-terminal mutation present in premalignant stem cells was combined with an N-terminal mutation. The first induced the expansion of stem cell compartment, the second maintained the myeloid lineage commitment, as observed in double mutated patients (125).

Runt-related transcription factor (RUNX1)

RUNX1 gene located on chromosome 21q22.12 and encodes for a transcription factor interacting with many cofactors and enhancers, thus playing an essential role in embryogenesis and hematopoiesis. The homozygous lack of RUNX1 is lethal, with mid-gestation death of embryos due to hemorrhagic necrosis of central nervous system and block of definitive hematopoiesis (126). The disruption of RUNX1 in adult models results in an increase of hematopoietic progenitors, defective megakaryocytic maturation and defective lymphocytic development. However, the functional changes induced by RUNX1 loss result in overt leukemia only after acquisition of additional mutations (127). Besides the involvement of RUNX1 in many recurrent chromosomal translocations, in AML also intragenic recurrent mutations in the functional domain and in the DNA binding domain of the protein have been found (128). RUNX1 mutations occur in 5–18% of adult AML, are mutually exclusive with recurrent genetic abnormalities included in the WHO classification or with complex karyotype but are often associated with trisomy of chromosome 13 and with deletion of chromosome 7. Patients with RUNX1-mutated AML are mostly older male, with secondary disease arising from an antecedent myelodysplastic syndrome, minimally differentiated (M0) cytology. RUNX1 mutations are associated with resistance to induction chemotherapy in about 30% of patients and with inferior EFS, DFS and OS (129,130). To date, allogeneic SCT appears the best option for increasing survival rate in patients harboring RUNX1 mutations (129).

KIT

The stem cell factor receptor (c-kit, CD117), officially known as “KIT proto-oncogene receptor tyrosine kinase” is a 145 kDa protein coded on chromosome 4(4q12) by a single copy gene of twenty-one exons (131). As FLT3, CSF-1R, PDGFRβ and PDGFRα, it belongs to type III receptor TK family. In the hematopoietic system, KIT is highly expressed in about 70% of CD34 positive cell, including lineage-restricted progenitor cells and immature cells capable of in vitro long-term hematopoiesis. Moreover, CD117 is expressed also on megakaryocytes. C-kit is downregulated in all lineages during maturation and, in mature cells, it is detectable only in mast-cells, in CD56+ natural killer cells and in activated platelets (132-136). SCF binding induces KIT dimerization, phosphorylation and activation of many downstream pathways, such as PI3K, MEK, RAS and RAF, involved in regulation of survival, proliferation and migration of hematopoietic cells.

In adult AML KIT mutations are found in 5% of patients, but higher frequencies are reported in the CBF subgroup (16–46%) (137,138). Most of them are point mutations in exon 17 (such as D816V) or in exon 8, with a gain of function leading to increased receptor activation upon SCF binding (139). However, other mutation on codon 816 or in different exons, insertion and deletion in exon 8, or internal tandem duplication of the juxtamembrane domain (exon 11), have been less commonly reported. The prognostic impact of KIT mutation is controversial. Many authors reported an increased relapse risk and reduced survival (140-142), while others did not find significant differences (143,144). In a meta-analysis including 2,933 patients with CBF AML, Chen and colleagues confirmed a negative effect of KIT mutations on relapse risk, but not on CR rate and OS; however, in the subgroup with t(8;21), a negative effect also on OS was observed (145). Besides, screening for KIT mutations can be useful for the possibility of targeting by TKIs, even though the results of a small phase II study of BCR/ABL1 inhibitor dasatinib as maintenance in CBF AML at high relapse risk suggest that efficacy of single agent dasatinib may be affected by the emergency of KIT-negative sub-clones resulting from spontaneous or dasatinib-driven clonal evolution (146).

RAS

RAS proto-oncogenes (NRAS, KRAS) encode for a membrane G protein of 21kDa associated with plasma and internal membranes of the cell through galectin 1 and galectin 3 anchor proteins. The engagement of receptors by growth factors determine a conformational change of RAS, followed by GTP hydrolysis and consequent activation of many downstream effectors involved in cell-cycle progression and proliferation, block of apoptosis and survival advantage, increased cell motility vesicles budding and transport (147).

In AML, activating NRAS mutations are described in 8–13% of adults, while KRAS mutations are less common and found only in 2% of patients; mutations occur mostly in codons 12, 13 or 61. NRAS mutations are more frequent in cases with t(3;5) and KRAS mutations in patients with inv(16) and younger than 60 years, but their prognostic impact remain still controversial. Despite small-size studies have hypothesized an adverse impact on outcome (148-150), the evaluation in larger number of patients did not confirm their negative effect (151,152). Since RAS activity depends on post-translational farnesylation, from the early 2000s many studies tried to target the RAS pathway with farnesyl-transferase inhibitor tipifarnib, with disappointing results (153-157).

Tumor protein p53 (TP53)

The TP53 gene codes for a DNA binding protein acting as a tumor suppressor. In response to cellular stress it promotes cell cycle arrest, apoptosis and DNA repair (158). Mutations of TP53 are more common in solid than in hematologic malignancies (159) and in AML they occur in 8 to 14% of all cases (8). A significant higher frequency is found in patients with complex karyotypes, where the incidence ranges from 69% to 73% (160). Moreover, in those patients TP53 mutations correlate with the total number of chromosomal abnormalities and with monosomal karyotype (161). Mutations are mostly single nucleotide changes and type of mutations and mutational allelic burden are similar in “de novo” and therapy-related AMLs (162), despite the frequency of mutations is higher in therapy-related disease. In general, TP53 alterations are associated with poorer prognosis, higher relapse rate and inferior EFS and OS. The negative prognostic significance of TP53 mutations appears independent from age, cytogenetics and all other co-occurring molecular alterations (162-164).

Wilms tumor 1 (WT1)

WT1 is a gene of 10 exomes located at chromosome 11p13, encoding for a transcription factor involved in cell growth and metabolism by modulating the expression of membrane receptors and growth factors, components of extracellular matrix, and genes affecting cell survival (165). In normal hematopoiesis WT1 expression is confined to the CD34 positive population, and acts as a suppressor gene regulating progenitor cell growth and maturation (166,167). In AML WT1 is overexpressed in most patients, and increased expression is associated with resistance to chemotherapy, high relapse rate and poor survival (168). However, the role of WT1 overexpression in leukemogenesis is not completely understood. Studies in murine models suggest that its pathogenic role may be context-specific and may depend from the temporal acquisition of co-occurring mutational events. Recurrent somatic loss-of-function mutations have been described in 6–13% of AML patients. These include deletions, insertion or base substitutions in exons 1, 7 and 9, resulting in the expression of a protein lacking the zinc-finger domain. As for gene overexpression, little is known about the leukemogenic role of mutated WT1. It has been recently hypothesized a role as epigenetic modifier, even if the pattern of genes deregulated by mutations remains under investigation (169). In adult AML WT1 mutations is associated with reduced survival and high relapse rate (170,171). The suggested perturbation of epigenome by WT1 mutations may open new therapeutic options employing epigenetic-targeted therapies.

Plant Homeodomain Finger 6 (PHF6)

The PHF6 gene consists of 11 exons coded on chromosome X, acting as a suppressor gene involved in neurogenesis and hematopoiesis. Recurrent mutations have been identified in 3–8% of AML patients and have been associated with adverse prognosis, especially in intermediate risk group (172). Van Vlierberghe and colleagues reported a higher frequency in males and in less mature subtypes (FAB M0-M2) and frequent association with other cooperative mutations (173).

DNA methyltransferase 3a (DNMT3A) mutations

The DNA methyltransferase family catalyze the formation of 5-methylcitosine by adding a methyl group to cytosine in CpG dinucleotides. The increased methylation of CpG islands results in transcriptional silencing of downstream genes (174). DNAMT3A mutations occur in 12–22% of adult AML, with higher frequency in patients with normal cytogenetics (175). DNAMT3A mutations are associated with older age and higher WBC count compared to the wild type counterpart. They result in the production of a truncated protein, with reduced methyltransferase activity through a missense mutation causing in most of cases an arginine to histidine substitution at codon R882. Even if the precise mechanism by which they contribute to leukemogenesis is not completely understood, it is well known that DNAMT3 mutations are an early event in leukemic transformation, may be present in pre-leukemic stem cells and can persist also after CR achievement (176,177). Regarding their clinical role, two recent meta-analysis including more than 10,000 patients confirmed a poor prognostic impact on OS and RFS in de novo adult patients (178,179). Nonetheless, improved outcome has been reported in intermediate cytogenetics patients receiving induction chemotherapy with high dose anthracyclines (180), suggesting their potential role as therapeutic marker. On the other hand, patients harboring DNAMT3A mutation show high response rates and superior OS by employing the DNA methyltransferase inhibitor decitabine (181,182) suggesting their usefulness in the therapeutic decision-making. Clinical trials evaluating the efficacy of DNA methyltranferase inhibitors decitabine and guadecitabine are ongoing (183-185).

Isocitrate dehydrogenase mutations (IDH1/2)

IDH1 and IDH2 genes code for two enzymes of the acid citric cycle, both catalyzing the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), to produce NADPH either in peroxisomes (IDH1) or in mitochondria (IDH2). NADPH has key functions in detoxification processes and α-KG affects the activity of many dioxygenases involved in different cellular processes and in epigenetic control of gene expression (186). Somatic mutations of IDH1 and IDH2 genes are among the most common mutations recurring in AML, with a prevalence of 4–9% and 8–19%, respectively; they are particularly frequent in CN-AML patients (172,187), often occur with trisomy 8, while co-occurrence of both mutation is very rare (188). IDH mutations detected at diagnosis tend to be stable during disease progression and, in general, patients do not acquire mutations during follow up (189). However, differences in detection limits or expansion of the mutant clone could uncover, at relapse, only apparently new mutations, complicating their use as a marker of minimal residual disease. All IDH1/2 mutations are heterozygous and consist in single amino-acid substitution at codon 132 in exon 4 of the IDH1 gene and codons 140 or 172 in exon 4 of IDH2. The mutated IDH (mIDH) leads to the formation and accumulation of the R enantiomer of 2-hydroxyglutarate (R-2-HG) that acts as an “oncometabolite” by inducing a dysregulation of epigenetic methylation processes and inhibition of α-KG enzymes, including the ten-eleven-translocation (TET) family. The consequent “hypermethylation phenotype” causes the transcriptional silencing of genes crucial for differentiation of hematopoietic progenitors, ultimately inducing a maturation arrest as well as an increase of progenitor cell numbers with high proliferative potential (190). Besides, hematopoietic cells harboring IDH mutations show a dramatic decrease of ataxia-telangiectasia mutated (ATM) protein, that represent the first trigger to recruit repair factors in response to DNA damage. The impaired DNA repair promotes the acquisition of additional mutations and clonal expansion of IDH mutated stem cells and favors the evasion of p53-mediated tumor suppression upon oncogenic stress. From a clinical point of view, patients carrying IDH mutations tend to be older and to have higher blast cell count and platelets count at diagnosis (191). To date, the prognostic impact of IDH1/2 mutations in AML remains unclear (192). A meta-analysis including 8121 patients concluded that those with mIDH1 have inferior OS, and in the subgroup with normal cytogenetics mIDH1 seemed to confer resistance to induction therapy resulting in a lower CR rate (193). Likewise, studies on prognostic significance of mIDH2 are inconsistent regarding all outcome variables. The different results among studies may depend from study methodology (i.e., many of them combine IDH1/IDH2 for the analysis) as well as from mutational context. However, regardless of prognostic role, considering their frequency and the oncogenic function, mIDH1/2 represents an excellent target for therapeutic purposes. Many selective mIDH inhibitors are in in preclinical development and many other in various stages of clinical investigation (194). They are able to bind the catalytic site of mIDH hindering the conformational changes causing R-2-HG production by reduction of α-KG (195) or binding a remote site which inactivate mIDH1 (196). Results of the phase I trial on the IDH2 inhibitor, AG221 (enasidenib), in relapsed/refractory patients demonstrated a mild, mostly gastrointestinal, toxicity. Six percent of patients developed an IDH-associated differentiation syndrome resembling that observed in acute promyelocytic leukemia during treatment with retinoic acid. Clinical efficacy was good with an overall response rate of 38.5%. CR was achieved in of 20.2% of treated patients (197) irrespective to the arginine mutation (R140 or R172). Amatangelo and colleagues, analyzing samples from patients included in that trial demonstrated that, in responsive patients enasidenib reduced intracellular R-2-HG and restored differentiation generating fully functional neutrophils (198). On the basis of these promising results, in August 2017 FDA approved the use of enasidenib for IDH2 mutated relapsed/refractory AMLs (199). A phase 3 trial evaluating enasidenib vs. conventional care in relapsed/refractory patients ≥60 years and a phase I/II trial assessing safety and tolerability of enasidenib in association with standard induction therapy are still ongoing (200). The recently reported results of phase I trial on the mIDH1 inhibitor ivosidenib (AG120), demonstrated similar efficacy and safety profile. Overall response rate was 41.6% and complete remission or complete remission with partial hematological recovery was obtained in 21.6%, with a median time to CR of 2.8 months. If appropriately managed, ivosidenib-associated adverse events (i.e., QT interval prolongation, differentiation syndrome and leukocytosis) did not require permanent discontinuation of the drug (201). Trails assessing safety, efficacy and tolerability of ivosidenib in combination with standard chemotherapy or with azacytidine in untreated patients harboring IDH1 mutation are currently recruiting (200).

Ten eleven translocation family member 2 (TET2) mutations

TET2 protein, coded on chromosome 4q24, converts 5-methyl- to 5-hydorxymethylcitosine with α-ketoglutarate as cofactor, playing a role in epigenetic regulation of cellular processes.

TET2 mutations have been found in 8–28% of AML cases, mostly in the exons 3–12, and are associated with reduction of the catalytic function or with impaired DNA targeting (202). The “hypermethylation status” resulting from TET2 mutations overlaps that observed in IDH1/2 mutated AML, suggesting the involvement of a common leukemogenic pathway. However, TET2 mutations are mutually exclusive with IDH mutations, supporting the hypothesis of a distinct leukemogenic mechanism (190). In humans TET2 inactivation is present in pre-leukemic stem cells and is associated with clonal expansion (203). Experimental models have demonstrated that the TET2 mutations-induced hypermethylation especially affects enhancer regions regulating tumor suppressor genes so facilitating leukemogenesis (204). The prognostic impact of TET2 mutations is still under debate. Some studies failed to find an association between TET2 mutation and outcome (205,206), while others demonstrated an inferior EFS in presence of TET2 mutations, either considering the whole population or in specific subgroups (such as CN-AML, age less than 65 years and ELN favorable risk) (172,207-209). Liu and colleagues performed a meta-analysis including 395 AML patients with TET2 mutations concluding that it could be considered an adverse prognostic factor in patients with normal karyotype (210).

Cohesin complex mutations

Cohesin complex consists of four protein subunits (SMC1A, SMC3, RAD21, STAG1/STAG2) involved in sister chromatid cohesion (211). By holding chromatin strands within the ring-like structure resulting from the four components assembly, it maintains the polarity of sister chromatids during mitosis. Besides, cohesin complex is involved gene expression regulation and in DNA repair (212). Mutations in the different subunits have been described in adult and in children with AML, resulting in a loss of function impairing chromatin accessibility. In vitro studies seem to suggest that cohesion mutation enforce stem cell programs by increasing serial “replating” ability and stemness-associated gene expression in more immature populations but may not be leukemogenic. The pre-leukemic phenotype would require a second hit to drive transformation, proposing cohesin mutations as potential targets for new therapies designed to change leukemic evolution. Despite the improved knowledge in cohesion function, their clinical impact on outcome is still unclear (213-215). Recently, Tsai and colleagues have first reported an association between cohesin mutations and superior OS and DFS in a series of 391 de novo adult AMLs (216).

Chromatin remodeling genes mutations

Additional sex comb like 1 (ASXL1) mutations

The gene encodes for a chromatin binding protein acting as activator or repressor of transcription in localized areas, leading to DNA and or histone modifications (217). Mutations occur in 3–5% of AML patients, but the frequency is higher in intermediate risk (11–17%), in patients with age ≥60 years and in secondary AML (218-220). In adults ASXL1 mutations have been associated with poor prognosis in intermediate risk AML (218) and in elderly patients with reduced CR and shorter survival (221).

BCL6 corepressor (BCOR) mutations

BCOR gene is located on chromosome X and the BCOR protein acts as transcriptional repressor of BCL6, interacting with histone deacetylases (222). Its loss of function impairs proliferation and differentiation of myeloid cells (223). Mutations are detected in about 4% of adult AML, and in 17% of those with normal cytogenetics, with a negative prognostic role (224).

Lysine (K) methyltransferase 2A (KMT2A) mutations

Previously termed mixed lineage leukemia (MLL) gene, is located at chromosome 11q23 and encodes for a protein with histone methyltransferase activity involved in regulation of gene expression through histone modification. Partial tandem duplication of KMT2A gene, occurring between exons 2 and 8, has been reported in 4–14% of AML cases and is associated with an inferior outcome especially in CN-AML (164,225).

Enhancer of Zeste Homologue 2 (EZH2) mutations

EZH2 is a histone methyltransferase involved in balancing between cell differentiation and renewal in hematopoietic progenitors (226). Mutations have been described in about 2% of adult AML, are more frequent in megakaryoblastic leukemia and in leukemia associated with Down syndrome and was correlated with inferior survival (227,228).

Spliceosomal machinery mutations

The spliceosome complex consists of five small nuclear ribonucleoproteins (snRNPs) and of their associated protein factors responsible for the removal of noncoding regions from pre-messenger RNAs (229). Alternative splicing is important in regulation of hematopoiesis and the different isoforms co-occur at different maturity stages of progenitor cells. An imbalance in the splicing machinery resulting in the prevalence of one splicing variant can activate alternative maturation programs and contribute to development of leukemia. Recurrent mutations of splicing factors involving SF3B1, U2AF1, SRSF2, and ZRSR2 are common in MDS and are, in general, associated with better clinical outcome. On the contrary, their frequency is low in de novo AML (4% for SF3B1, 4.9% for SRSF2, 6.5% for U2AF1, and <1% for ZRSR2), are associated with older age and male gender and predict lower CR rates, shorter DFS and OS (230).


Conclusions

Over the last two decades the combination of conventional cytogenetics, PCR-based techniques and Sanger sequencing have already changed the diagnostic and prognostic approach to AML. In the last 5 years the more extensive use of next generation sequencing (NGS) has further refined the molecular landscape of AML, allowing the identification of recurrent mutations in most of patients, also within previously defined subgroups, yielding to an updating of AML classification. The wider use of NGS has also provided new insights in understanding leukemogenesis, by identifying the leukemia-initiating mutations and analyzing clonal evolution at relapse. On the other hand, the huge data outputs within few years has led clinicians to face the dilemma of how to translate this diagnostic information into clinical care, integrating the results of emerging technologies with more traditional laboratory features, and how to reduce the complexity of generated data into groups sharing cellular pathways potentially targetable by new drugs.

Efforts should be focused on the development of standardized diagnostic algorithms, able to identify the molecular markers permitting alternative therapeutic approaches and at the same time useful for minimal residual disease monitoring. In our opinion, only this way will eventually translate the massive amount of new biological data in significant advance in survival for patients with AML that, sadly, to date remains a dreadful disease.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. O'Donnell MR, Tallman MS, Abboud CAN, et al. Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw 2013;11:1047-55. [Crossref] [PubMed]
  2. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65. [Crossref] [PubMed]
  3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83. [PubMed]
  4. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-47. [Crossref] [PubMed]
  5. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20. [Crossref] [PubMed]
  6. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36. [Crossref] [PubMed]
  7. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405. [Crossref] [PubMed]
  8. Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74. [Crossref] [PubMed]
  9. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016;374:2209-21. [Crossref] [PubMed]
  10. Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505. [Crossref] [PubMed]
  11. Sportoletti P, Grisendi S, Majid SM, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008;111:3859-62. [Crossref] [PubMed]
  12. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005;437:147-53. [Crossref] [PubMed]
  13. Tanaka M, Sasaki H, Kino I, et al. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res 1992;52:3372-7. [PubMed]
  14. Nozawa Y, Van Belzen N, Van der Made AC, et al. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996;178:48-52. [Crossref] [PubMed]
  15. Shields LB, Gercel-Taylor C, Yashar CM, et al. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig 1997;4:298-304. [Crossref] [PubMed]
  16. Subong EN, Shue MJ, Epstein JI, et al. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999;39:298-304. [Crossref] [PubMed]
  17. Tsui KH, Cheng AJ, Chang P, et al. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 2004;64:839-44. [Crossref] [PubMed]
  18. Skaar TC, Prasad SC, Sharareh S, et al. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol 1998;67:391-402. [Crossref] [PubMed]
  19. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010;10:301-9. [Crossref] [PubMed]
  20. Colombo E, Marine JC, Danovi D, et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002;4:529-33. [Crossref] [PubMed]
  21. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86. [Crossref] [PubMed]
  22. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66. [Crossref] [PubMed]
  23. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007;92:519-32. [Crossref] [PubMed]
  24. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009;27:171-81. [Crossref] [PubMed]
  25. Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Sci 2013;22:545-56. [Crossref] [PubMed]
  26. Meloni G, Mancini M, Gianfelici V, et al. Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica 2009;94:298-300. [Crossref] [PubMed]
  27. Bolli N, Galimberti S, Martelli MP, et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol 2006;7:350-2. [Crossref] [PubMed]
  28. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006;66:3310-6. [Crossref] [PubMed]
  29. Falini B, Mecucci C, Saglio G, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008;93:439-42. [Crossref] [PubMed]
  30. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:596-604. [Crossref] [PubMed]
  31. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008;105:3945-50. [Crossref] [PubMed]
  32. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13-27. [Crossref] [PubMed]
  33. Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009;114:3024-32. [Crossref] [PubMed]
  34. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005;106:3618-20. [Crossref] [PubMed]
  35. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854-61. [Crossref] [PubMed]
  36. Díaz-Beyá M, Rozman M, Pratcorona M, et al. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. Blood 2010;116:6147-6148. [Crossref] [PubMed]
  37. Liu Y, He P, Liu F, et al. Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. Mol Clin Oncol 2014;2:275-81. [Crossref] [PubMed]
  38. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20. [Crossref] [PubMed]
  39. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-6. [Crossref] [PubMed]
  40. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-54. [Crossref] [PubMed]
  41. Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013;121:2734-8. [Crossref] [PubMed]
  42. Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 2014;124:3441-9. [Crossref] [PubMed]
  43. Schnittger S, Bacher U, Kern W, et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011;25:1297-304. [Crossref] [PubMed]
  44. Koh Y, Park J, Bae EK, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. Int J Hematol 2009;90:1-5. [Crossref] [PubMed]
  45. Pastore F, Greif PA, Schneider S, et al. The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PLoS One 2014;9:e109759. [Crossref] [PubMed]
  46. Alpermann T, Schnittger S, Eder C, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica 2016;101:e55-58. [Crossref] [PubMed]
  47. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220-31. [Crossref] [PubMed]
  48. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1;and CBFB-MYH11 acute myeloid leukemias. Blood 2010;115:198-205. [Crossref] [PubMed]
  49. Qi W, Shakalya K, Stejskal A, et al. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene 2008;27:4210-20. [Crossref] [PubMed]
  50. Di Matteo A, Franceschini M, Chiarella S, et al. Molecules that target nucleophosmin for cancer treatment: an update. Oncotarget 2016;7:44821-40. [Crossref] [PubMed]
  51. Balusu R, Fiskus W, Rao R, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011;118:3096-106. [Crossref] [PubMed]
  52. Perera Y, Farina HG, Gil J, et al. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol Cancer Ther 2009;8:1189-96. [Crossref] [PubMed]
  53. De Cesare M, Cominetti D, Doldi V, et al. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget 2015;6:13119-32. [Crossref] [PubMed]
  54. Etchin J, Montero J, Berezovskaya A, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia 2016;30:190-9. [Crossref] [PubMed]
  55. Etchin J, Berezovskaya A, Conway AS, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia 2017;31:143-50. [Crossref] [PubMed]
  56. Li FF, Yi S, Wen L, et al. Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro. Acta Pharmacol Sin 2014;35:806-13. [Crossref] [PubMed]
  57. Mukherjee H, Chan KP, Andresen V, et al. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants. ACS Chem Biol 2015;10:855-63. [Crossref] [PubMed]
  58. Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood 2015;125:3455-65. [Crossref] [PubMed]
  59. Nabbouh AI, Hleihel RS, Saliba JL, et al. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. Cancer 2017;123:1662-73. [Crossref] [PubMed]
  60. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003;3:173-83. [Crossref] [PubMed]
  61. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004;103:1901-8. [Crossref] [PubMed]
  62. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12:1333-7. [Crossref] [PubMed]
  63. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624-31. [Crossref] [PubMed]
  64. Kiyoi H, Ohno R, Ueda R, et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002;21:2555-63. [Crossref] [PubMed]
  65. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-73. [Crossref] [PubMed]
  66. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-14. [PubMed]
  67. Zheng R, Friedman AD, Levis M, et al. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 2004;103:1883-90. [Crossref] [PubMed]
  68. Sallmyr A, Fan J, Datta K, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 2008;111:3173-82. [Crossref] [PubMed]
  69. Scheijen B, Ngo HT, Kang H, et al. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004;23:3338-49. [Crossref] [PubMed]
  70. Lee BH, Tothova Z, Levine RL, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007;12:367-80. [Crossref] [PubMed]
  71. Li L, Piloto O, Nguyen HB, et al. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood 2008;111:3849-58. [Crossref] [PubMed]
  72. Chu SH, Heiser D, Li L, et al. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell 2012;11:346-58. [Crossref] [PubMed]
  73. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002;99:310-8. [Crossref] [PubMed]
  74. Medinger M, Passweg JR. Acute myeloid leukaemia genomics. Br J Haematol 2017;179:530-42. [Crossref] [PubMed]
  75. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35. [Crossref] [PubMed]
  76. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9. [Crossref] [PubMed]
  77. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000;111:190-5. [Crossref] [PubMed]
  78. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-80. [PubMed]
  79. Bienz M, Ludwig M, Leibundgut ED, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-24. [Crossref] [PubMed]
  80. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80. [Crossref] [PubMed]
  81. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012;30:735-41. [Crossref] [PubMed]
  82. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3;RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97:3589-95. [Crossref] [PubMed]
  83. Daver N, Liu Dumlao T, Ravandi F, et al. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk 2013;13:435-40. [Crossref] [PubMed]
  84. Rombouts WJ, Blokland I, Lowenberg B, et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000;14:675-83. [Crossref] [PubMed]
  85. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:3622-6. [Crossref] [PubMed]
  86. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-84. [Crossref] [PubMed]
  87. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-9. [PubMed]
  88. Pratz KW, Sato T, Murphy KM, et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115:1425-32. [Crossref] [PubMed]
  89. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-5. [Crossref] [PubMed]
  90. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9. [Crossref] [PubMed]
  91. Spiekermann K, Bagrintseva K, Schoch C, et al. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002;100:3423-5. [Crossref] [PubMed]
  92. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005;106:265-73. [Crossref] [PubMed]
  93. Lacayo NJ, Meshinchi S, Kinnunen P, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004;104:2646-54. [Crossref] [PubMed]
  94. Chan PM. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model. Protein Cell 2011;2:108-15. [Crossref] [PubMed]
  95. Grundler R, Miething C, Thiede C, et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005;105:4792-9. [Crossref] [PubMed]
  96. Bailey E, Li L, Duffield AS, et al. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc Natl Acad Sci U S A 2013;110:21113-8. [Crossref] [PubMed]
  97. Müller TA, Grundler R, Istvanffy R, et al. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype. Leukemia 2016;30:1725-33. [Crossref] [PubMed]
  98. Marhäll A, Heidel F, Fischer T, et al. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Ann Hematol 2018;97:773-80. [Crossref] [PubMed]
  99. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008;111:1552-9. [Crossref] [PubMed]
  100. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007;110:1262-70. [Crossref] [PubMed]
  101. Mead AJ, Gale RE, Hills RK, et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008;112:444-5; author reply 445. [Crossref] [PubMed]
  102. Assi R, Ravandi F. FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. Am J Hematol 2018;93:553-63. [Crossref] [PubMed]
  103. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93. [Crossref] [PubMed]
  104. Fiedler W, Kayser S, Kebenko M, et al. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol 2015;169:694-700. [Crossref] [PubMed]
  105. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294-301. [Crossref] [PubMed]
  106. Knapper S, Russell N, Gilkes A, et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 2017;129:1143-54. [Crossref] [PubMed]
  107. Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010;24:1437-44. [Crossref] [PubMed]
  108. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96:62-8. [Crossref] [PubMed]
  109. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62. [Crossref] [PubMed]
  110. Röllig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2;randomised controlled trial. Lancet Oncol 2015;16:1691-9. [Crossref] [PubMed]
  111. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121:4655-62. [Crossref] [PubMed]
  112. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017;377:454-64. [Crossref] [PubMed]
  113. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013;31:3681-7. [Crossref] [PubMed]
  114. Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 2017;129:257-60. [Crossref] [PubMed]
  115. Wang ND, Finegold MJ, Bradley A, et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995;269:1108-12. [Crossref] [PubMed]
  116. Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 2004;21:853-63. [Crossref] [PubMed]
  117. Friedman AD. C/EBPalpha in normal and malignant myelopoiesis. Int J Hematol 2015;101:330-41. [Crossref] [PubMed]
  118. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-33. [Crossref] [PubMed]
  119. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088-91. [Crossref] [PubMed]
  120. Fasan A, Haferlach C, Alpermann T, et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia 2014;28:794-803. [Crossref] [PubMed]
  121. Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010;28:2739-47. [Crossref] [PubMed]
  122. Bacher U, Schnittger S, Macijewski K, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood 2012;119:4719-22. [Crossref] [PubMed]
  123. Li HY, Deng DH, Huang Y, et al. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. Eur J Haematol 2015;94:439-48. [Crossref] [PubMed]
  124. Tawana K, Wang J, Renneville A, et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 2015;126:1214-23. [Crossref] [PubMed]
  125. Bereshchenko O, Mancini E, Moore S, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 2009;16:390-400. [Crossref] [PubMed]
  126. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 1996;93:3444-9. [Crossref] [PubMed]
  127. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004;10:299-304. [Crossref] [PubMed]
  128. Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009;114:5352-61. [Crossref] [PubMed]
  129. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011;29:1364-72. [Crossref] [PubMed]
  130. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 2012;30:3109-18. [Crossref] [PubMed]
  131. d'Auriol L, Mattei MG, Andre C, et al. Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum Genet 1988;78:374-6. [Crossref] [PubMed]
  132. Papayannopoulou T, Brice M, Broudy VC, et al. Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile. Blood 1991;78:1403-12. [PubMed]
  133. Lammie A, Drobnjak M, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-25. [Crossref] [PubMed]
  134. Avraham H, Vannier E, Cowley S, et al. Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood 1992;79:365-71. [PubMed]
  135. Ogawa M, Matsuzaki Y, Nishikawa S, et al. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 1991;174:63-71. [Crossref] [PubMed]
  136. Matos ME, Schnier GS, Beecher MS, et al. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993;178:1079-84. [Crossref] [PubMed]
  137. Jones D, Yao H, Romans A, et al. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 2010;49:182-91. [PubMed]
  138. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004;89:920-5. [PubMed]
  139. Kohl TM, Schnittger S, Ellwart JW, et al. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005;105:3319-21. [Crossref] [PubMed]
  140. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904-11. [Crossref] [PubMed]
  141. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791-9. [Crossref] [PubMed]
  142. Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 2013;27:1891-901. [Crossref] [PubMed]
  143. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010;115:2372-9. [Crossref] [PubMed]
  144. Jung HA, Maeng CH, Park S, et al. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia. Anticancer Res 2014;34:1037-45. [PubMed]
  145. Chen W, Xie H, Wang H, et al. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0146614. [Crossref] [PubMed]
  146. Boissel N, Renneville A, Leguay T, et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 2015;100:780-5. [Crossref] [PubMed]
  147. Alvarado Y, Giles FJ. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 2007;12:271-84. [Crossref] [PubMed]
  148. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993;82:590-9. [PubMed]
  149. Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994;83:1603-11. [PubMed]
  150. Radich JP, Kopecky KJ, Willman CL, et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990;76:801-7. [PubMed]
  151. Bacher U, Haferlach T, Schoch C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107:3847-53. [Crossref] [PubMed]
  152. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005;106:2113-9. [Crossref] [PubMed]
  153. Zimmerman TM, Harlin H, Odenike OM, et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol 2004;22:4816-22. [Crossref] [PubMed]
  154. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007;109:1387-94. [Crossref] [PubMed]
  155. Erba HP, Othus M, Walter RB, et al. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 2014;38:329-33. [Crossref] [PubMed]
  156. Kirschbaum MH, Synold T, Stein AS, et al. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia 2011;25:1543-7. [Crossref] [PubMed]
  157. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-9. [Crossref] [PubMed]
  158. Tominaga O, Hamelin R, Remvikos Y, et al. p53 from basic research to clinical applications. Crit Rev Oncog 1992;3:257-82. [PubMed]
  159. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9. [Crossref] [PubMed]
  160. Haferlach C, Dicker F, Herholz H, et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22:1539-41. [Crossref] [PubMed]
  161. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119:2114-21. [Crossref] [PubMed]
  162. Ok CY, Patel KP, Garcia-Manero G, et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 2015;8:45. [Crossref] [PubMed]
  163. Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J 2015;5:e331. [Crossref] [PubMed]
  164. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012;120:2963-72. [Crossref] [PubMed]
  165. Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868-76. [Crossref] [PubMed]
  166. Ellisen LW, Carlesso N, Cheng T, et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001;20:1897-909. [Crossref] [PubMed]
  167. Svedberg H, Richter J, Gullberg U. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. Leukemia 2001;15:1914-22. [Crossref] [PubMed]
  168. Barragán E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-33. [PubMed]
  169. Rampal R, Figueroa ME. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica 2016;101:672-9. [Crossref] [PubMed]
  170. Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009;115:3719-27. [Crossref] [PubMed]
  171. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010;115:5222-31. [Crossref] [PubMed]
  172. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-89. [Crossref] [PubMed]
  173. Van Vlierberghe P, Patel J, Abdel-Wahab O, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia 2011;25:130-4. [Crossref] [PubMed]
  174. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet 2013;14:204-20. [Crossref] [PubMed]
  175. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-33. [Crossref] [PubMed]
  176. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328-33. [Crossref] [PubMed]
  177. Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014;111:2548-53. [Crossref] [PubMed]
  178. Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2014;9:e93353. [Crossref] [PubMed]
  179. Yuan XQ, Peng L, Zeng WJ, et al. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients. Medicine (Baltimore) 2016;95:e3519. [Crossref] [PubMed]
  180. Marková J, Michkova P, Burckova K, et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol 2012;88:128-35. [Crossref] [PubMed]
  181. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012;26:1106-7. [Crossref] [PubMed]
  182. Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28:1774-83. [Crossref] [PubMed]
  183. Pastore F, Levine RL. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica 2016;101:269-78. [Crossref] [PubMed]
  184. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood 2016;127:71-8. [Crossref] [PubMed]
  185. Gardin C, Dombret H. Hypomethylating Agents as a Therapy for AML. Curr Hematol Malig Rep 2017;12:1-10. [Crossref] [PubMed]
  186. Molenaar RJ, Radivoyevitch T, Maciejewski JP, et al. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta 2014;1846:326-41. [PubMed]
  187. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011;118:5593-603. [Crossref] [PubMed]
  188. Platt MY, Fathi AT, Borger DR, et al. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn 2015;17:661-8. [Crossref] [PubMed]
  189. Lin CC, Hou HA, Chou WC, et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol 2014;89:137-44. [Crossref] [PubMed]
  190. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-67. [Crossref] [PubMed]
  191. Aref S. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Clin Lymphoma Myeloma Leuk 2015;15:550-5. [Crossref] [PubMed]
  192. O'Donnell MR, Tallman MS, Abboud CN, et al. Acute Myeloid Leukemia, Version 3.2017;NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:926-57. [Crossref] [PubMed]
  193. Feng JH, Guo XP, Chen YY, et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res 2012;2:254-64. [PubMed]
  194. Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 2017;31:272-81. [Crossref] [PubMed]
  195. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622-6. [Crossref] [PubMed]
  196. Jones S, Ahmet J, Ayton K, Ball M, et al. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells. J Med Chem 2016;59:11120-37. [Crossref] [PubMed]
  197. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722-31. [Crossref] [PubMed]
  198. Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 2017;130:732-41. [Crossref] [PubMed]
  199. Kim ES. Enasidenib: First Global Approval. Drugs 2017;77:1705-11. [Crossref] [PubMed]
  200. Ragon BK, DiNardo CD. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia. Curr Hematol Malig Rep 2017;12:537-46. [Crossref] [PubMed]
  201. DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 2018;378:2386-98. [Crossref] [PubMed]
  202. Meldi KM, Figueroa ME. Cytosine modifications in myeloid malignancies. Pharmacol Ther 2015;152:42-53. [Crossref] [PubMed]
  203. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012;4:149ra118. [Crossref] [PubMed]
  204. Rasmussen KD, Jia G, Johansen JV, et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev 2015;29:910-22. [Crossref] [PubMed]
  205. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010;116:1132-5. [Crossref] [PubMed]
  206. Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012;30:1350-7. [Crossref] [PubMed]
  207. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-81. [Crossref] [PubMed]
  208. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1;TET2;and TET3 alterations in myeloid malignancies. Blood 2009;114:144-7. [Crossref] [PubMed]
  209. Weissmann S, Alpermann T, Grossmann V, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012;26:934-42. [Crossref] [PubMed]
  210. Liu WJ, Tan XH, Luo XP, et al. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leuk Lymphoma 2014;55:2691-8. [Crossref] [PubMed]
  211. Kim JS, He X, Orr B, et al. Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2. PLoS Genet 2016;12:e1005865. [Crossref] [PubMed]
  212. Mazumdar C, Majeti R. The role of mutations in the cohesin complex in acute myeloid leukemia. Int J Hematol 2017;105:31-6. [Crossref] [PubMed]
  213. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10. [Crossref] [PubMed]
  214. Shiba N, Yoshida K, Shiraishi Y, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol 2016;175:476-89. [Crossref] [PubMed]
  215. Thol F, Bollin R, Gehlhaar M, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123:914-20. [Crossref] [PubMed]
  216. Tsai CH, Hou HA, Tang JL, et al. Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer J 2017;7:663. [Crossref] [PubMed]
  217. Katoh M, Katoh M. Identification and characterization of ASXL2 gene in silico. Int J Oncol 2003;23:845-50. [PubMed]
  218. Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013;27:82-91. [Crossref] [PubMed]
  219. Fernandez-Mercado M, Yip BH, Pellagatti A, et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One 2012;7:e42334. [Crossref] [PubMed]
  220. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011;118:6920-9. [Crossref] [PubMed]
  221. Alpermann T, Haferlach C, Eder C, et al. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients. Leuk Res 2015;39:265-72. [Crossref] [PubMed]
  222. Huynh KD, Fischle W, Verdin E, et al. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 2000;14:1810-23. [PubMed]
  223. Cao Q, Gearhart MD, Gery S, et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia 2016;30:1155-65. [Crossref] [PubMed]
  224. Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011;118:6153-63. [Crossref] [PubMed]
  225. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254-61. [Crossref] [PubMed]
  226. Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia 2014;28:44-9. [Crossref] [PubMed]
  227. Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013;45:1293-9. [Crossref] [PubMed]
  228. Larsson CA, Cote G, Quintas-Cardama A. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11:815-27. [Crossref] [PubMed]
  229. Lee Y, Rio DC. Mechanisms and Regulation of Alternative Pre-mRNA Splicing. Annu Rev Biochem 2015;84:291-323. [Crossref] [PubMed]
  230. Hou HA, Liu CY, Kuo YY, et al. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget 2016;7:9084-101. [Crossref] [PubMed]
doi: 10.21037/jlpm.2018.09.08
Cite this article as: Damiani D, Tiribelli M. Molecular landscape in adult acute myeloid leukemia: where we are where we going? J Lab Precis Med 2019;4:17.